R-CVP

Phase 3Small molecule

AstraZeneca

R-CVP is one of 76 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Untreated Follicular LymphomaRecruiting

Follicular LymphomaActive, not recruiting

LymphomaPhase 3

Active, not recruiting

Untreated Follicular LymphomaPhase 3

Recruiting

Follicular LymphomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

R-CVP

AstraZeneca

Phase 3

1 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Norvir

AbbVie

Preclinical

1 4

Nuvigil

NNuvo Research GmbH

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

PEG-Intron

Merck & Co.

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 3Recruiting

Untreated Follicular Lymphoma

NCT06549595

Clinical

Trials by Indication[1]

Lymphoma1 trial

Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)

Terminated· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 3·NCT00384111·26 enrolled

Follicular Lymphoma1 trial

Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma

Unknown status·FFondazione Italiana Linfomi - ETS·Phase 3·NCT00774826·534 enrolled

Untreated Follicular Lymphoma1 trial

A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06549595·1,018 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for R-CVP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — R-CVP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for R-CVP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

R-CVP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Lymphoma1 trial

Follicular Lymphoma1 trial

Untreated Follicular Lymphoma1 trial

References

Drug Info

Quick Facts

Related News